Shevach Research Group

The major focus of the Cellular Immunology Section over the past 25 years has been furthering our understanding of the function of T regulatory cells (Tregs) that express the transcription factor Foxp3. Our group was one of the first in the world to realize the importance of Treg and we performed many of the initial studies that described their phenotype and function. The study of Tregs is now one of the most active areas of research in basic and clinical immunology and the therapeutic use of Treg is now in the clinic. It was originally assumed that Treg were a dedicated lineage of cells that developed only from thymic precursors, but more recent studies have clearly documented that Foxp3+ T cells also develop from conventional T cells (Tconv) in extra-thymic peripheral sites in vivo, and these are termed peripherally induced Tregs (pTregs). Treg can also be generated in culture in the presence of transforming growth factor-b1 (TGF-b1) and are termed induced Tregs (iTreg). The relative importance of tTreg and pTreg is unknown. 

Although most of our studies deal with Tregs in mouse models, over the past 15 years we have also carried out studies on human Tregs (hTregs) derived from normal donors. Our ongoing studies are described below and have been divided up into five major projects with significant overlap between the projects. We also intentionally validate new and novel findings that we learn in one species with similar studies in another species, as there appears to be conservation of many aspects of Treg function across the species.

Cell Immunology Fig Image

Two fundamentally different suppressor modes characterize Treg suppressor mechanisms. In the “active” mode, Treg cells secrete immunoinhibitory molecules that exert their effects on other cell types. In contrast, in the “counteractive” mode Treg cells are actively engaged in removing vital components from other cells types including antigen, costimulatory molecules, cytokines, and inflammatory signals thereby decreasing the activation of T effector cells. B. Akkaya and E.M. Shevach, Cellular immunology 2020.

Credit: NIAID

Ethan M. Shevach, M.D.

Chief, Cellular Immunology Section

Contact: For contact information, search the NIH Enterprise Directory.

Education:

M.D., 1967, Boston University

Dr. Shevach received his M.D. from Boston University in 1967. Following clinical training, he joined the Laboratory of Immunology as a senior staff fellow in 1972, was appointed a senior investigator in 1973, and became a section chief in 1987. Dr. Shevach served as editor-in-chief of the Journal of Immunology from 1987 to 1992 and editor-in-chief of Cellular Immunology from 1996 to 2007. Dr. Shevach is the author of more than 450 papers.

Learn more about Ethan M. Shevach, M.D.

Ethan Shevach, M.D.

Angela Thornton, Ph.D.

Staff Scientist

Contact: For contact information, search the NIH Enterprise Directory.

Education:

Ph.D., Microbiology and Immunology, The George Washington University 

B.A., Biology, University of Virginia  

Pat Korty, M.S.

Microbiologist

Contact: For contact information, search the NIH Enterprise Directory.

Education:

M.S., Animal Science, The University of Maryland 

Abir Panda, Ph.D.

Research Fellow (VP)

Contact: For contact information, search the NIH Enterprise Directory.

Education:

Ph.D., Biotechnology, Bose Institute, India

Abir received his Ph.D. in biotechnology in 2016 from Bose Institute, Kolkata, India. He is currently studying the critical roles of NK, Antigen Presenting Cells (APC), and Tregs in maintaining immune homeostasis in the steady-state and augmentation of anti-viral and anti-tumor immunity in murine models and human cancer patients.

Learn more about Abir Panda, Ph.D.

Xuan Xie, Ph.D.

Visiting Postdoctoral Fellow

Contact: For contact information, search the NIH Enterprise Directory.

Education:

Ph.D., Biological Sciences, Tokyo Institute of Technology, Japan

Xuan received her Ph.D. in biological sciences in 2018 from Tokyo Institute of Technology, Japan, where she studied the functions of 2 deubiquitinases (USP5 and USP13) during the assembly and disassembly of stress granules in Professor Masayuki Komada’s laboratory. She is currently working on novel approaches for the development of human Treg modulating mAbs for the treatment of cancer or...

Learn more about Xuan Xie, Ph.D.

Yong-Hee Kim, M.D., Ph.D.

Visiting Postdoctoral Fellow

Contact: For contact information, search the NIH Enterprise Directory.

Education:

M.D., Ph.D., Immunology, Seoul National University College of Medicine, South Korea

Yong-Hee received his Ph.D. in immunology in 2013 from Seoul National University College of Medicine, South Korea where he worked in Chung-Gyu Park’s laboratory. Currently, he is studying pTreg induction and transplantation tolerance.

Learn more about Yong-Hee Kim, M.D., Ph.D.

Mohammad Nizam Mansoori, Ph.D.

Visiting Postdoctoral Fellow

Contact: For contact information, search the NIH Enterprise Directory.

Education:

Ph.D., Osteoimmunology, Council of Scientific and Industrial Research – Central Drug Research Institute, India 

Nizam received his Ph.D. in the area of osteoimmunology from the Council of Scientific and Industrial Research – Central Drug Research Institute (CSIR-CDRI), India, in 2017. He joined NIH as a Visiting Scientist in 2017. Currently, he is studying the mechanism of antigen specific CD8 T cell regulation by iTregs both in vitro and in vivo. In 2020, he received an AAI Trainee abstract award.

Learn more about Mohammad Nizam Mansoori, Ph.D.

Melissa Blain, M.S.

Biologist

Contact: For contact information, search the NIH Enterprise Directory.

Education:

M.S., Medical Biology, C.W. Post Campus of Long Island University 

B.S., Biochemical Pharmacology, University at Buffalo

Melissa Blain is a research biologist in the Shevach laboratory since 2008. She has a M.S. in medical biology with a concentration in hematology and immunology, and a B.S. in biochemical pharmacology.

Learn more about Melissa Blain, M.S.

Sruthi Chempati, M.S.

Biologist

Contact: For contact information, search the NIH Enterprise Directory.

Education:

M.S., Biological Sciences, Texas A&M University  

B.S., Biotechnology, Jawaharlal Nehru Technological University

Sruthi Chempati is a research biologist in the Shevach laboratory. She received a M.S. in biological sciences and a B.S. in biotechnology. Prior to joining the Shevach laboratory, she worked in an immunology laboratory focused on generation of EGFRvIII CAR T cells and in a R&D laboratory focused on murine tumor model studies with Flow Cytometry technical competency.

Learn more about Sruthi Chempati, M.S.

Madalyn Jones, B.S.

Postbaccalaureate Fellow

Contact: For contact information, search the NIH Enterprise Directory.

Education:

B.S., Biomedical Sciences, Troy University

Madalyn is currently working to identify the role of the transcription factor Helios in human CD8+ T cells. She received her B.S. in biomedical sciences from Troy University. Madalyn plans to pursue an M.D./Ph.D. and continue research as a physician-scientist.

Learn more about Madalyn Jones, B.S.

Neil Yang, B.S.

Postbaccalaureate Fellow

Contact: For contact information, search the NIH Enterprise Directory.

Education:

B.S., Biology, Case Western Reserve University

Neil received a B.S. in biology from Case Western Reserve University in 2021. His current work involves the study of the transcription factor Helios in conventional T cells.

Learn more about Neil Yang, B.S.

Soha Kazmi, B.S.

Postbaccalaureate Fellow 

Contact: For contact information, search the NIH Enterprise Directory.

Education:

B.S., Biology and Chemistry, University of Florida

Soha received a B.S. in biology and chemistry from the University of Florida in 2022. She is currently studying Ly49/LILRs- MHC Class-I interactions in anti-viral and anti-tumor immunity in murine models and human patient samples.

Learn more about Soha Kazmi, B.S.

Sooho Myoung, B.S.

Postbaccalaureate Fellow

Contact: For contact information, search the NIH Enterprise Directory.

Education:

B.S., Statistics, The University of North Carolina at Chapel Hill

Sooho received a B.S. in statistics from the University of North Carolina at Chapel Hill in 2023. Prior to joining NIH, he worked in Dr. Gowthami Arepally’s laboratory at Duke University Medical Center, where he studied the role of complement in heparin-induced thrombocytopenia. Currently, he is studying the transcription factor Helios in conventional T cells. He plans to pursue a career as a...

Learn more about Sooho Myoung, B.S.

Content last reviewed on